Sir, Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA We are grateful that Dan and Mihai Călugăru 1 took interest in our article. The subject of optimal intensity of anti-VEGF treatment has been discussed previously following the publication of a similar claims data study, which described real-world treatment patterns of ranibizumab and aflibercept for macular oedema secondary to central retinal vein occlusion. [2] [3] [4] Our study aimed to understand whether the frequency of ophthalmology visits for patients treated with ranibizumab (Lucentis) and dexamethasone implant (Ozurdex) differed in routine clinical practice in the United States for the treatment of macular oedema secondary to retinal vein occlusion (RVO). 5 Comparing treatment frequency was a secondary objective in our study, with the resulting estimate of ranibizumab treatment frequency being consistent with that previously observed by Lotery and Regnier. 2 We agree with Dan and Mihai Călugăru that the observed treatment patterns in our analysis should not be interpreted as the optimal treatment frequency. The frequency of treatment administration neither reflects the treatment frequency observed in clinical trials 6,7 nor provides data on visual acuity outcomes attained by the treated cohort. In our discussion, we outline the limitation that visual acuity data were not available in the claims database at our disposal for the conduct of this study. 5 The Callanan et al. study aimed to demonstrate the noninferiority of dexamethasone implant compared to ranibizumab with respect to mean average change from baseline best-corrected visual acuity (BCVA) over 12 months in patients with diabetic macular oedema. The primary outcome of non-inferiority between treatments was met; however, statistically significant and clinically meaningful differences were observed in mean change from baseline in BCVA favouring ranibizumab. Furthermore, a saw-tooth pattern in central retinal thickness (CRT), indicative of frequent fluctuation of CRT, was observed in the dexamethasone arm. This is in contrast to the sustained improvements in CRT for ranibizumab-treated eyes during the study period. 8 Superiority of dexamethasone implant vs ranibizumab in anatomical outcomes was not demonstrated in the Callanan study. Moreover, the authors did not find the claim of superior anatomical outcomes associated with dexamethasone implant adequately supported by randomised clinical trial evidence. 1 Studies linking treatment patterns to real-world clinical outcomes in RVO will be an important part of understanding outcomes attained by patients in routine clinical practice.
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We read with interest the article 'Advances of optical coherence tomography in myopia and pathologic myopia.' 1 In this article, the authors cite the original definition of domeshaped macula (DSM) by Gaucher et al 2 as 'an inward bulge of the macula within the concavity of a posterior staphyloma in highly myopic eyes,' and go on to expound the 'many uncertainties' regarding DSM. Specifically, the authors outline several theories for the development of DSM: 'resistance to deformation of scleral staphyloma, scleral infolding through the collapse of the posterior portion of the eye wall, and tangential vitreoretinal traction.' 1 We would like to present a novel mechanical explanation for the development and pathophysiology of DSM based on the fundamental physical principles of Pascal's principle and Laplace's law. Pascal's principle 3 tells us that the internal pressure inside of a closed vessel, such as the eye as a whole (or a blood vessel or a tube containing fluid), is the same throughout, despite variations in radius or diameter of the vessel. Laplace's law 4 goes on to define the relationship between the radius of that vessel and wall tension, given the constant internal pressure (Figure 1) . In an enclosed vessel such as a theoretical eye with uniform elasticity and 
